Cheng, FWT;
Fan, M;
Wong, CKH;
Chui, CSL;
Lai, FTT;
Li, X;
Wan, EYF;
... Wong, ICK; + view all
(2022)
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases.
Kidney International
, 102
(4)
pp. 922-925.
10.1016/j.kint.2022.07.018.
Preview |
Text
The effectiveness and safety of mRNA.pdf - Published Version Download (203kB) | Preview |
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed a serious threat to individuals with underlying chronic kidney disease (CKD). People with CKD are immunocompromised and therefore result in poorer outcomes including increased risk of hospitalization and mortality after COVID-19.1 Despite the availability of COVID-19 vaccines, current data on the vaccine efficacy in individuals with CKD are limited to surrogate endpoints such as antibody titers. As a result, a dedicated study is required to evaluate the effectiveness and safety of COVID-19 vaccines for the CKD population.
Archive Staff Only
 |
View Item |
